Physician profile
Daniel Tesfaye
NPI 1023033065
$14,757.63
in general payments reported to CMS, 2019-2025
59 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $1,099 · 2021: $1,790 · 2022: $2,264 · 2023: $2,707 · 2024: $2,818 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,196 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,196.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,782.35 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $808.03 | 2019-2025 | |
| Lundbeck LLC | $767.88 | 2019-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $648.80 | 2020-2025 | |
| Lilly USA, LLC | $613.26 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Alexion Pharmaceuticals, INC. | $607.38 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $574.54 | 2022-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $563.66 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Pfizer INC. | $526.89 | 2019-2025 | |
| Amgen INC. | $502.26 | 2019-2025 | Uplizna |
| Argenx US, INC. | $490.05 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $466.77 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Neurelis, INC. | $460.30 | 2023-2025 | Valtoco |
| Avanir Pharmaceuticals, INC. | $379.58 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $365.61 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tesfaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.